AI Consensus Investment Thesis
GILD: Gilead Sciences Stock Price, Analysis & Forecast: 1 Year and 5 Year Targets
Gilead Sciences: 1-Year and 5-Year Forecast Outlook and Rating
Gilead Sciences (GILD) has an immediate Hold & Monitor consensus AI recommendation, based on 14 AI analysts.
The 1-year target is $159 for , with +1.59% expected return (+2.94% including net dividends) and a NEUTRAL rating.
The 5-year target is $191 for , with +22.04% expected return (+31.00% including net dividends) and a NEUTRAL rating.
Latest available market price: USD 157, as of 20 Oct 2026.
Dividend calculation details
Calculated net annual dividend yield: 1.45%. As of 2026-10-20.
Gross TTM: 2.08% · Two-year annualized gross: 2.04%.
Tax withholding assumption: 30% (US). One-off special payments are excluded.
Original published assumption: 2.5% per year.
Return estimates compound the net annual yield at a constant rate over the stated return horizon (the remaining time to the fixed target date for current returns): (1 + price return) × (1 + net annual yield)years − 1.
Targets retain their original publication dates. Returns use the dated market close and the time remaining to each fixed target date. Current ratings also require fresh quotes and analysis, with more than 90 days remaining. Past targets have no forward return. Eligibility checked .
Gilead Sciences Flagship Insight
Biopharma Cash Engine Confronts Impending Regulatory Price Squeeze and Patent Cliffs
Sharp divergence defines the analytical outlook, contrasting transformative twice-yearly capsid prevention adoption against mandatory statutory Medicare pricing concessions. Entrenched virology cash generation comfortably absorbs recent multi-billion acquired research charges, yet looming exclusivity horizons and capital allocation discipline dictate whether long-term valuation multiples can expand sustainably.
How were the Investment Thesis and Forecasts created?
14 AI advisors, guided by 9 analytical frameworks, contribute to the deep analysis by iPulse AI Engine.
Elon Musk (Visionary)
Michael Burry (Vulture)
Warren Buffett (Value Purist)
Superintelligence (Anthropologist)
Universal Investor (Polymath)
Sherlock Holmes (Whistleblower)
Ray Dalio (Strategist)
J.P. Morgan (Titan)
Machiavelli (Insider)
Ran across these frontier AI models
Google Gemini 3.8 Flash
Anthropic Claude Opus 5
OpenAI GPT-6 Astra
Latest published deep-analysis batch. Audit published forecasts in full transparency
Gilead Sciences: forecast questions
What is Gilead Sciences (GILD)'s 1-year price forecast?
Gilead Sciences's 1-year target is $159 for Sept 2027. The current AI rating is NEUTRAL. The expected return from the recorded close is +1.59%, or +2.94% modeled return including net dividends. Latest available market price: USD 157, as of 20 Oct 2026. The target date is fixed; this is not a new rolling forecast.
What is Gilead Sciences (GILD)'s 5-year price forecast?
Gilead Sciences's 5-year target is $191 for Sept 2031. The current AI rating is NEUTRAL. The expected return from the recorded close is +22.04%, or +31.00% modeled return including net dividends. Latest available market price: USD 157, as of 20 Oct 2026. The target date is fixed; this is not a new rolling forecast.
What is the return basis?
Latest available market price: USD 157, as of 20 Oct 2026. These are model projections, not guaranteed future prices.
How can I compare the AI opinions and audit past Gilead Sciences forecasts?
14 AI analysts contribute to this publication. AI Opinions shows individual advisor forecasts and reasoning. Forecast History preserves earlier published batches; their figures describe their original publication, not today's outlook.
How does an AI-generated forecast for Gilead Sciences differ from Wall Street analyst consensus?
Wall Street consensus aggregates estimates from human analysts. For listed companies, these typically include brokerage price targets, earnings forecasts and ratings. iPulse AI's forecast for Gilead Sciences is a separate AI consensus generated through its own research workflow. Different inputs, forecast dates, assumptions and weighting can therefore produce different targets.
We believe the era of investment research conducted only by human analysts is drawing to a close. Frontier models increasingly match or exceed expert work on selected professional benchmarks, including evaluations covering financial analysis. Research on multi-model synthesis also shows that combining model responses can improve on a single model's output in the tasks studied.
iPulse AI generates transparent investment research and market forecasts using a swarm of AI configurations, analytical frameworks and frontier models. The workflow applies multiple verification, challenge and synthesis layers, with selective editorial review under Russlan Ramdowar, Editor-in-Chief. Published assumptions, disagreements and past forecasts remain available so readers can inspect the reasoning and audit outcomes.
For a research cycle covering 426 assets with 14 perspectives per asset, our internal workload model estimates approximately 114,000 hours of traditional analyst work. It assumes 16 hours per individual research report, 28 hours per consensus for synthesis and validation, plus shared data preparation. Parallel AI execution allows a deep-analysis cycle across hundreds of assets to complete in up to one day. The human-hours figure is an illustrative workload estimate, rather than measured time savings. Our research methodology explains the automated workflow.
Gilead Sciences: Investment Thesis Summary
Dotted terms link to the glossary; hover or focus for a preview. Browse technical terms
If you invest $10,000 in Gilead Sciences at the latest market close (20 Oct 2026): $13,100 by Sept 2031 versus $13,751 for S&P 500 benchmark.
Returns use the same dated market close, fixed targets and remaining dividend period as the forecast table.
* Return is calculated incl. 1.5% net dividend yield for Gilead Sciences.
The fundamental investment case rests on the economic transition from daily antiretroviral treatment to an ultra-long-acting capsid inhibitor platform. Core virology generates over twelve billion dollars in recurring annual cash flow, funding substantial shareholder distributions and pipeline absorption. However, equity valuation sensitivity centers on the impending Inflation Reduction Act price negotiation for bictegravir starting in 2028 alongside outer-year patent expirations. While the market excessively discounted headline accounting losses stemming from acquired research charges, durable capital appreciation requires commercial prevention expansion and disciplined business development execution to outpace legislated reimbursement erosion across government channels.
Key insights
- Commercial conversion toward twice-yearly prevention expands the total addressable prophylaxis market rather than merely cannibalizing existing daily oral regimens across commercial books.
- Accounting charges from acquired in-process research mask underlying forty-percent operating margins, yet external pipeline acquisitions consume genuine balance-sheet liquidity and elevate integration risks.
- Restrictive benchmark interest rates elevate equity hurdle rates, dictating that total shareholder returns depend upon cash compounding rather than terminal multiple expansion.
Gilead Sciences: 5 Year Consensus Forecast
20 quarterly price targets, returns and rationale, with advisor range and benchmark
Forward returns are updated using the latest market close price of USD 157, as of 20 Oct 2026.
Dividend calculation details
Calculated net annual dividend yield: 1.45%. As of 2026-10-20.
Gross TTM: 2.08% · Two-year annualized gross: 2.04%.
Tax withholding assumption: 30% (US). One-off special payments are excluded.
Original published assumption: 2.5% per year.
Return estimates compound the net annual yield at a constant rate over the stated return horizon (the remaining time to the fixed target date for current returns): (1 + price return) × (1 + net annual yield)years − 1.
The consensus target follows an expert-weighted price path synthesized from 14 AI advisor opinions. See Opinion weights and rationale for the exact allocation and reasoning.
Forecast methodology and reference values
Published targets are anchored on 18 Sept 2026 at USD 150. Original quarter-to-quarter target changes are retained. Forward returns use the remaining time to each fixed target date.
The pessimistic and optimistic advisor base cases are the lowest and highest published advisor base-case targets for each quarter. The advisor at either extreme can change between quarters. Benchmark values are in USD.
Scroll the table horizontally to read every column.
| Quarter | Evidence-Weighted Consensus Price Path | Individual Advisor Range & Reference Forecasts | ||||||
|---|---|---|---|---|---|---|---|---|
| Consensus target (USD) | Forecast quarter-to-quarter price change | Forward price return | Forward return incl. net dividends | Forecast rationale | Pessimistic Advisor Base Case (USD) | Optimistic Advisor Base Case (USD) | S&P 500 benchmark (USD) | |
| $152 | +1.18% | -2.88% | -2.65% | Third-quarter results reaffirm base virology acceleration as Yeztugo adoption expands. Investors look past transient acquisition accounting, though elevated Treasury yields and caution ahead of late-December anito-cel regulatory decisions temper broad valuation multiple expansion. | $144 | $156 | $750 | |
| $155 | +1.76% | -0.96% | -0.38% | Resolution of key regulatory binaries, including anito-cel and once-weekly oral lenacapavir reviews, supports constructive sentiment. Clean fourth-quarter earnings restore positive reported profitability, confirming resilient cash conversion despite ongoing launch commercialization costs. | $140 | $161 | $736 | |
| $157 | +1.49% | +0.31% | +1.27% | Commercial launch execution for once-weekly prevention demonstrates healthy volume growth across domestic channels. Resilient core treatment sales absorb legacy product attrition, while restrictive monetary policy across global central banks continues capping broader market multiples. | $133 | $167 | $743 | |
| $159 | +1.46% | +1.59% | +2.94% | Mid-year financial disclosures confirm underlying operating margin stability near forty percent. Solid free cash flow generation easily funds continuous quarterly dividend disbursements, though preliminary legislative rhetoric regarding drug price negotiations prompts modest sector hesitation. | $135 | $172 | $755 | |
| $158 | -0.44% | +0.95% | +2.66% | Market models begin discounting upcoming 2028 Medicare negotiated price resets on Biktarvy. Strong quarterly volume gains and initial Livdelzi contributions cushion sentiment, but valuation multiple compression moderates overall equity performance into year-end. | $130 | $176 | $776 | |
| $160 | +1.18% | +2.23% | +4.33% | Initial implementation of negotiated Medicare pricing introduces visible gross-to-net discount pressure across exposed domestic channels. However, accelerating global Yeztugo sales and clean full-year 2027 operating cash flow demonstrate durable franchise defense. | $126 | $181 | $787 | |
| $163 | +1.78% | +4.15% | +6.67% | Encouraging Phase 3 data for anito-cel in earlier multiple myeloma settings validates pipeline diversification. Surging prevention adoption offsets government pricing concessions, allowing operational cash flows to resume balance-sheet de-leveraging. | $127 | $186 | $803 | |
| $165 | +1.04% | +5.42% | +8.38% | Late-stage clinical trial progression for once-yearly injectable lenacapavir enhances long-term terminal value visibility. Operating margins remain resilient as manufacturing efficiencies take hold, easily absorbing commercial overhead and sustaining steady equity accumulation. | $122 | $190 | $812 | |
| $167 | +1.14% | +6.70% | +10.09% | Robust second-half cash conversion and disciplined capital allocation support another dividend increase alongside selective share repurchases. International commercial expansion for Yeztugo accelerates, reinforcing defensive institutional demand despite volatile broader equity trading. | $120 | $196 | $839 | |
| $170 | +1.77% | +8.62% | +12.46% | Full-year 2028 financial reporting demonstrates that non-viral specialty products contribute expanding profit shares. Virology cash flows remain resilient against statutory pricing adjustments, supporting modest per-share earnings growth and steady valuation recovery. | $116 | $200 | $851 | |
| $173 | +1.75% | +10.54% | +14.86% | Commercial rollout of next-generation combination therapies preserves high HIV market share against generic threats in older classes. Free cash flow margins remain elite near thirty percent, underwriting opportunistic buybacks across consolidating markets. | $119 | $206 | $872 | |
| $174 | +1.00% | +11.18% | +15.95% | Solid oncology contributions from Trodelvy and advancing antibody-drug conjugate platforms offset routine volume decay in mature antiviral lines. Earnings compound predictably, though approaching loss-of-exclusivity horizons for legacy assets keeps valuation multiples tethered. | $114 | $208 | $886 | |
| $177 | +1.73% | +13.09% | +18.37% | Anticipation of regulatory filings for once-yearly prevention regimens reinforces terminal confidence in virology leadership. High operating cash flow allows management to rebuild liquid reserves while retiring maturing corporate notes into year-end. | $112 | $214 | $910 | |
| $179 | +1.13% | +14.37% | +20.14% | Full-year 2029 results confirm sustainable normalized free cash flow exceeding twelve billion dollars. Strong cash conversion and consistent shareholder distributions provide robust downside insulation as broader macroeconomic growth displays late-cycle cooling. | $108 | $220 | $916 | |
| $181 | +0.88% | +15.65% | +21.92% | Global adoption of long-acting lenacapavir formulations reaches mature scale, successfully migrating patients off aging single-tablet regimens. Oncology revenues expand toward targeted run-rates, defending group operating profitability against persistent government reimbursement friction. | $109 | $225 | $937 | |
| $184 | +1.47% | +17.56% | +24.39% | Terminal multiple discounting emerges as analysts evaluate patent settlement timelines for core therapies entering the five-year forecast horizon. High owner earnings yield and disciplined share retirements fully cushion equity prices against valuation contraction. | $106 | $225 | $947 | |
| $186 | +1.08% | +18.84% | +26.20% | Year-end financial results highlight durable multi-therapeutic diversification spanning virology, liver disease, and hematology. Robust balance-sheet liquidity and conservative interest coverage support consistent per-share compounding despite mature industry valuation multiples. | $104 | $229 | $970 | |
| $188 | +1.11% | +20.12% | +28.01% | Reporting of 2030 annual performance validates unencumbered cash generation and another progressive dividend hike. Stable prescription retention across commercial payer books demonstrates the enduring clinical stickiness of the underlying antiviral ecosystem. | $105 | $236 | $980 | |
| $189 | +0.71% | +20.76% | +29.16% | International market penetration and pipeline milestone execution sustain predictable mid-single-digit top-line growth. Easing macroeconomic capital costs provides mild valuation support, balancing terminal multiple compression as generic settlement deadlines edge perceptibly closer. | $103 | $241 | $1,000 | |
| $191 | +0.92% | +22.04% | +31.00% | The five-year strategic horizon concludes with the core franchise successfully bridged onto next-generation long-acting regimens. Total shareholder returns reflect steady cash compounding and capital return delivery rather than speculative multiple re-rating. | $104 | $246 | $1,012 | |
Show remaining 18 quartersShow first 2 quarters only
All 20 quarters are displayed in the table above.
Gilead Sciences Stock Analysis & Scenarios Deep Dive
Gilead Sciences: Alpha Gap & Repricing Catalysts
Market Narrative
What does the market currently expect? Prevailing market sentiment anchors on Gilead's recent stock surge, treating flawless clinical efficacy for lenacapavir in prevention as guaranteed long-term growth. Meanwhile, generalist commentary remains unsettled by the headline second-quarter acquisition write-off, assuming upcoming Medicare price negotiations and looming patent horizons will inevitably impair earnings durability. Pricing models largely dismiss acquisition charges as one-off noise while treating terminal cash flows as static annuities.
Alpha Gap
What is the biggest difference between market expectations and our AI forecasts? The reports establish that the crowd underestimates underlying cash durability while overestimating near-term multiple expansion. The analytical edge centers on recognizing that the ten-billion-dollar GAAP loss was an accounting expensing of upfront acquisition research, not operating cash depletion; trailing free cash flow exceeds thirteen billion dollars. However, the crowd mistakenly treats twice-yearly prevention as an instant offset to 2028 Medicare price cuts on Biktarvy. True edge lies in modeling steady per-share cash compounding rather than speculative valuation multiple re-rating.
Repricing Catalyst
What could make the market recognize and close that gap? The primary convergence catalyst is the regulatory review window spanning the late December 2026 anito-cel decision and the February 2027 PDUFA action for once-weekly oral lenacapavir. Tangible approval data, accompanied by fourth-quarter disclosures restoring positive GAAP earnings and quantifying paid commercial prescription adoption for Yeztugo, will compel institutional analysts to replace headline accounting skepticism with updated cash flow models reflecting sustainable core franchise compounding.
Gilead Sciences: Sentiment and Timing
What do sentiment, volatility, and the market-recognition cycle suggest about the thesis timing?
- Greed and Fear Sentiment
- Balanced
- Volatility Regime
- Moderate
- Convergence Cycle Position
- Momentum
While reports broadly agree on moderate market volatility, views diverge sharply regarding cycle positioning. Some perspectives diagnose euphoric overshoot after the stock's run to recent highs, whereas others observe early momentum supported by unencumbered cash generation.
Macro Regime Fit
Does the current market environment support the thesis? The prevailing macroeconomic regime of restrictive interest rates and elevated sovereign bond yields presents a mixed setup. Inelastic biological demand for essential antivirals and robust free cash flow insulate operational earnings from economic deceleration, but benchmark yields near five percent elevate capital hurdle rates, capping equity valuation multiple expansion.
Advisor Disagreement
What do our AI Advisors disagree about most? The sharpest analytical disagreement centers on terminal valuation and capital allocation efficacy. Bullish frameworks view recent multi-billion-dollar acquisition charges as benign accounting artifacts that secured high-growth oncology assets ahead of lenacapavir's commercial ascendancy. Conversely, skeptical frameworks argue that management repeatedly incinerates surplus virology cash on low-return external pipelines while ignoring inevitable 2028 Medicare price cuts and patent cliffs. Resolving this tension requires observing whether twice-yearly prevention adoption and anito-cel commercial revenues generate genuine operating margin expansion before statutory pricing discounts materialize.
Gilead Sciences: Critical Influencing Factors
Near-certain positive forcesTop Drivers & Tailwinds
Near-certain forces that support the investment thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Driver / Tailwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Lenacapavir long-acting prevention commercial hegemony | Innovation And Product | +22% | +26% | Twice-yearly injectable lenacapavir transforms HIV prophylaxis by eliminating daily oral pill adherence friction following stellar efficacy in pivotal PURPOSE trials. Rapid commercial adoption expands the addressable prevention cohort into high-margin recurring territory. This clinical breakthrough establishes durable pricing power and long-term cash generation extending well beyond legacy tenofovir formulations. |
| Biktarvy cash engine patent settlement runway | Competitive Positioning | +15% | +18% | Biktarvy retains domestic treatment dominance, commanding nearly half the HIV patient base with exceptional resistance barriers and high switching costs. Established legal settlements defer full generic entry until the mid-2030s. This unyielding commercial annuity delivers massive baseline cash flow that self-funds clinical pipeline development and corporate capital returns. |
| High-conversion free cash flow owner compounding | Capital Allocation | +11% | +10% | Minimal maintenance capital expenditure below two percent of revenue allows underlying operations to convert over twelve billion dollars into annual normalized free cash flow. This prolific cash generation supports steady dividend growth and opportunistic share repurchases, providing an enduring equity valuation floor and reliable per-share compounding through macroeconomic cycles. |
| Oncology and liver specialty franchise scaling | Sector And Industry | +10% | +12% | Trodelvy label expansion into first-line metastatic breast cancer alongside commercial launches of Livdelzi in primary biliary cholangitis establishes meaningful non-viral diversification. These high-margin specialty therapies leverage existing commercial infrastructure to accelerate operating leverage, progressively buffering terminal cash flows against eventual loss-of-exclusivity transitions in mature antivirals. |
Near-certain negative forcesTop Frictions & Headwinds
Near-certain forces that could slow, cap, or damage the thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Friction / Headwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Medicare drug price negotiation margin compression | Regulatory | -13% | -15% | Mandatory Medicare Part D price negotiations under the Inflation Reduction Act target top-selling blockbusters, with statutory maximum fair prices for Biktarvy scheduled for 2028 implementation. Enforced discounts and expanding rebate liabilities compress gross-to-net realizations on substantial domestic volume, imposing a permanent structural drag on core virology profit margins. |
| Impending mid-decade virology patent cliff discounting | Competitive Positioning | -11% | -8.0% | Financial models progressively discount terminal valuation multiples as loss-of-exclusivity horizons for legacy antiretroviral components approach during the 2030s. While lifecycle migration strategies aim to transition patients to newer combinations, the sheer revenue magnitude of exposed franchises creates persistent multiple compression that caps equity appreciation despite solid near-term cash generation. |
| Aggressive external pipeline acquisition cash burn | Capital Allocation | -9.0% | -10% | Deploying over thirteen billion dollars into external clinical acquisitions creates acute headline accounting losses through acquired research expensing while depleting liquid reserves. Slower commercialization payback, trial attrition, or integration bottlenecks across acquired cell therapy and antibody-drug conjugate assets threaten return on invested capital and constrain near-term share repurchase flexibility. |
| Elevated cost of capital valuation headwind | Macroeconomic And Macrofinancial | -8.0% | -4.0% | The higher-for-longer interest rate environment with sovereign Treasury yields hovering near five percent increases corporate hurdle rates and widens equity discount rates. High risk-free yields diminish the relative yield appeal of defensive pharmaceutical dividends, compressing institutional price-to-earnings multiples and demanding that shareholder returns rely strictly on fundamental earnings growth. |
Gilead Sciences: What Could Break or Accelerate the Thesis
Event Risk Score: Very Low 16/100Asset-level relative pressure from clustered consensus frictions and tail risks. This is not the probability or risk score of an individual force.Plausible downside scenariosTail Risks
Tail yet plausible downside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Accelerated generic Biktarvy patent litigation breach | 24% | -26% | An unexpected federal court ruling invalidating bictegravir formulation patents prior to established settlement horizons would expose the core fourteen-billion-dollar franchise to premature generic erosion. Wiping out billions in high-margin operating cash flow before next-generation regimens fully migrate patients would force immediate dividend freezes, credit rating pressure, and severe institutional equity liquidation. |
| Catastrophic acquired oncology pipeline clinical write-downs | 26% | -20% | Confirmatory Phase 3 trial failures or severe toxicities across newly acquired antibody-drug conjugates or cell therapies by 2028 would dismantle non-HIV diversification. Significant clinical setbacks would mandate multi-billion-dollar intangible impairments, permanently destroying invested capital. Disillusioned investors would enforce a steep conglomerate discount, contracting forward price-to-earnings multiples to depressed historical troughs. |
Plausible upside scenariosTail Opportunities
Tail yet plausible upside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Once-yearly lenacapavir formulation regulatory triumph | 35% | +26% | Pivotal Phase 3 PURPOSE 365 trial readouts validating once-yearly intramuscular lenacapavir would revolutionize preventive healthcare by late 2028. Perfect viral protection combined with annual dosing would completely monopolize global prophylaxis and eliminate adherence dropouts. Peak sales could surpass seven billion dollars, driving substantial upward revisions to long-term earnings and expanding valuation multiples. |
| Anito-cel frontline multiple myeloma dominance | 32% | +20% | Pivotal trial data establishing superior complete response durability and zero delayed neurotoxicity for anito-cel could secure accelerated approval in second-line or frontline multiple myeloma by 2028. Displacing incumbent CAR-T therapies would transform cell therapy into a four-billion-dollar oncology cornerstone, vindicating recent acquisition capital deployment and driving significant institutional multiple re-rating. |
Company Financial AnalysisGilead Sciences: Earnings and Financials Analysis by AI
Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included. View latest Gilead Sciences financials here.
Earnings and financials
Gilead's headline earnings display a dramatic split between accounting figures and operational reality. For the second quarter of 2026, the company reported an eye-catching net loss of over ten billion dollars, yet this paper deficit was driven almost entirely by one-time charges for acquired research. In stark contrast, underlying business performance remained exceptionally strong. Base product revenue climbed ten percent year-over-year, propelled by twelve percent expansion in core HIV medicines and surging prevention demand. Trailing free cash flow exceeded thirteen billion dollars, demonstrating that the underlying cash spigot continues generating robust organic profits.
Revenue, earnings, and cash flow
The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | USD 29.4B | USD 8.5B | USD 9.5B |
| 2024 | USD 28.8B | USD 480M | USD 10.3B |
| 2023 | USD 27.1B | USD 5.7B | USD 7.4B |
| 2022 | USD 27.3B | USD 4.6B | USD 8.3B |
| 2021 | USD 27.3B | USD 6.2B | USD 10.8B |
Valuation context: historical P/E
The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.
| Fiscal year | P/E | Earnings basis | Currency basis | Ticker / reporting |
|---|---|---|---|---|
| 2025 | 18.1x | TTM | Native | USD / USD |
| 2024 | >100x | TTM | Native | USD / USD |
| 2023 | 18.0x | TTM | Native | USD / USD |
| 2022 | 23.6x | Annual | Native | USD / USD |
| 2021 | 14.7x | Annual | Native | USD / USD |
P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.
Profitability and margins
Gilead commands extraordinary pricing power that keeps underlying profitability among the highest in global healthcare. Gross profit margins consistently hover near seventy-nine percent, sustained by monopolistic antiviral treatments and low manufacturing costs for core tablets. While reported operating margins experienced a temporary paper collapse due to mid-2026 acquisition write-offs, underlying non-GAAP operating margins remain formidable near forty-nine percent. Looking ahead, statutory Medicare price negotiation starting in 2028 will compress net realizations, but rapid adoption of premium preventive formulations should help preserve consolidated operating profitability above forty percent.
The table compares up to five fiscal years of operating income and reported profitability margins.
| Fiscal year | Operating income | Operating margin | Net margin |
|---|---|---|---|
| 2025 | USD 11.7B | 39.7% | 28.9% |
| 2024 | USD 1.7B | 5.8% | 1.7% |
| 2023 | USD 7.6B | 28.0% | 20.9% |
| 2022 | USD 7.3B | 26.9% | 16.8% |
| 2021 | USD 9.9B | 36.3% | 22.8% |
Balance sheet and leverage
Gilead's balance sheet reflects substantial financial resilience tempered by recent acquisition spending. Liquid cash reserves contracted to approximately three billion dollars by mid-2026 after funding multi-billion-dollar upfront purchases. Gross debt stands near twenty-six billion dollars, yet debt obligations remain comfortably staggered across future years. The true anchor of balance-sheet safety is powerful cash conversion. Generating over twelve billion dollars in annual operating cash flow gives the company more than ten times interest coverage. This dependable cash generation allows management to comfortably service debt and support shareholder dividends without facing solvency risks.
The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.
| Fiscal year | Total debt | Cash + short-term investments | Reported net cash / (debt) | Debt less (cash + short-term investments), calculated | Current ratio |
|---|---|---|---|---|---|
| 2025 | USD 24.9B | USD 9.6B | USD 17.4B net debt | USD 15.3B | 1.55x |
| 2024 | USD 26.7B | USD 11.6B | USD 16.7B net debt | USD 15.1B | 1.60x |
| 2023 | USD 25B | USD 7.3B | USD 18.9B net debt | USD 17.7B | 1.43x |
| 2022 | USD 25.2B | USD 6.4B | USD 19.8B net debt | USD 18.8B | 1.29x |
| 2021 | USD 26.7B | USD 6.5B | USD 21.4B net debt | USD 20.2B | 1.27x |
Reported net debt retains the source definition, which can deduct cash alone. Cash plus short-term investments is broader liquidity; the separately calculated column subtracts that full amount from total debt for the same fiscal period and currency. Reported net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.
Capex and investment intensity
Management maintains an extraordinarily capital-efficient physical footprint, spending less than two percent of total revenue on property and equipment. Producing small-molecule pills and biologic therapies requires minimal heavy industrial machinery, freeing up operational cash for intellectual property reinvestment. However, true investment intensity happens through external dealmaking. Management deployed over eleven billion dollars in cash during early 2026 to purchase biotechnology pipelines spanning cellular therapy and oncology. While physical capital needs remain light, commercial success now hinges upon turning these costly acquired scientific programs into profitable approved drugs.
The table compares up to five fiscal years of capital expenditure and research-and-development investment.
| Fiscal year | Capital expenditure | R&D spend |
|---|---|---|
| 2025 | USD 563M | USD 5.8B |
| 2024 | USD 523M | USD 5.9B |
| 2023 | USD 585M | USD 5.7B |
| 2022 | USD 728M | USD 5B |
| 2021 | USD 579M | USD 4.6B |
Behind the synthesisGilead Sciences: How Each Individual AI Forecaster Opinion Shapes the Global Consensus
This publication’s recorded synthesis allocated voting influence across 14 advisor opinions. The weights and rationales below are retained from that synthesis.
The evidence across reports establishes a consistent fundamental pattern: headline GAAP net losses in mid-2026 reflect an accounting charge for acquired research rather than operational cash deterioration, with underlying base revenues expanding ten percent and generating over twelve billion dollars in recurring free cash flow. Weighting prioritizes reports grounded in primary SEC filings, verified patent settlement schedules extending Biktarvy exclusivity to 2036, and CMS statutory pricing timelines. Lower weights are assigned to extreme contrarian cases projecting immediate collapse or unconstrained multiple expansion. While the bear case rightly highlights that acquired pipelines deplete liquidity and Medicare price negotiations will compress domestic margins by 2028, it overlooks proven patent duration and rapid twice-yearly prevention adoption. Conversely, peak-multiple bull cases disregard competitive five-percent Treasury yields. The relative weights reflect balanced per-share cash compounding, favoring rigorously evidenced analyses over speculative narratives.
All 14 opinions
Universal Investor AI
The Polymath
Anthropic Claude Opus 5 · 2026-07-24 releaseWeight: 13.0%
Demonstrating premier evidentiary rigor through primary SEC 10-Q citations, FDA approval milestones, and White House pricing pacts, this analysis delivers superior causal clarity. It meticulously dissects the acquired research expensing while modeling realistic long-term compounding across virology and oncology, justifying the highest relative weight in the consensus path.
Universal Investor AI
The Polymath
OpenAI GPT-6 Astra · 2026-09-03 releaseWeight: 12.0%
Anchored in verified primary SEC disclosures and official CMS regulatory determinations, this report provides exceptional evidentiary quality. It rigorously reconciles reported accounting losses with normalized cash flow while incorporating realistic margin friction from federal pricing negotiations and cost of capital benchmarks, justifying a leading weight in the overall synthesis.
Sherlock Holmes AI
The Whistleblower
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 10.0%
This report provides outstanding forensic examination of balance-sheet liquidity, debt maturity schedules, and non-GAAP margin reconciliation. It accurately models the timing of oral lenacapavir catalysts alongside realistic regulatory price headwinds. Its high evidentiary grounding and balanced long-term return profile warrant a substantial conviction weight.
Universal Investor AI
The Polymath
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 9.0%
Presenting thorough analysis of Biktarvy generic patent settlements extending to 2036 alongside verified Trodelvy first-line label expansions, this report establishes high evidentiary quality. It convincingly explains why underlying business acceleration easily absorbs transient accounting charges, warranting a high weight reflecting its balanced, evidence-backed operational optimism.
Ray Dalio AI
The Strategist
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 8.0%
This perspective excels in contextualizing biopharmaceutical cash generation within restrictive macroeconomic tightening and sovereign yield competition. It recognizes that equity returns must stem from organic operational earnings compounding rather than terminal multiple expansion. Its sound macro transmission mechanisms justify an above-average weight despite lighter company-specific pipeline granular detail.
Universal Investor AI
The Polymath
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 7.0%
This analysis demonstrates solid causal consistency, recognizing that trailing accounting losses reflect one-off transaction charges rather than operational decay. It correctly balances lenacapavir launch execution against upcoming Medicare price negotiations. However, the lack of granular primary filing receipts justifies a measured weight relative to more thoroughly documented peers.
Niccolo Machiavelli AI
The Insider
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 7.0%
This perspective offers valuable insights into global access voluntary licensing and diplomatic insulation from populist price controls. It correctly identifies how upfront M&A expensing distorts headline metrics while core revenues expand. The weight reflects this strong political and institutional analysis, balanced against somewhat optimistic oncology commercial assumptions.
Warren Buffett AI
The Value Seeker
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 7.0%
Offering a disciplined owner-earnings framework, this analysis properly emphasizes capital-light economics and high cash conversion. It soundly identifies valuation risks at current trading multiples while acknowledging durable competitive moats. A solid weight is warranted, though slight repetition of generalized value tropes keeps it below primary filing-grounded reports.
Michael Burry AI
The Vulture
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 6.0%
This report provides a credible discipline check on valuation, highlighting how high benchmark Treasury yields compress pharmaceutical price-to-earnings multiples. It accurately models statutory pricing drag and acquisition integration costs, though it somewhat underestimates the margin durability and total addressable market expansion delivered by twice-yearly injectable prevention regimens.
Elon Musk AI
The Visionary
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 6.0%
This analysis astutely diagnoses management's persistent tendency to deplete operational cash through speculative oncology acquisitions. It balances this friction against lenacapavir's biological moat. While offering sharp causal mechanisms, its somewhat cynical narrative on corporate capital allocation is tempered by evidence of disciplined underlying free cash flow generation.
Warren Buffett AI
The Value Seeker
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 5.0%
This assessment provides a healthy skepticism regarding margin of safety and liquidity depletion following aggressive M&A disbursements. However, its conservative assumption of owner earnings fails to fully credit rapid Yeztugo commercial adoption and proven legal patent insulation, justifying a modest weight that preserves its prudent cautionary signals.
J.P. Morgan AI
The Titan
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 4.0%
This report provides strong enthusiasm for Yeztugo but incorporates overly aggressive multiple expansion assumptions that disregard the prevailing high interest-rate regime. While correctly identifying core virology durability, its terminal enterprise valuation expansion exceeds prudent risk boundaries. A moderate weight preserves its commercial insight without overcommitting to its exuberant trajectory.
Superintelligence AI
The Anthropologist
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 3.0%
While providing a useful contrarian warning regarding Biktarvy patent expiry and historical oncology capital destruction, this report overstates structural operational decay. Projecting severe persistent negative equity returns ignores thirteen billion dollars in annual free cash flow and proven generic settlement protection extending into the 2030s, warranting a restricted weight.
Superintelligence AI
The Anthropologist
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 3.0%
While offering detailed pipeline progression scenarios across oncology and long-acting prevention, this report assumes an overly optimistic multiple re-rating and rapid earnings acceleration. It underestimates structural drag from statutory Medicare price negotiations and elevated cost of capital, warranting a low weight to avoid skewing the consensus trajectory upward.
References & Context
Research Provenance
Analysis generated by iPulse AI Engine v7 using recorded market data, operating under the editorial standards and supervision of Russlan Ramdowar, Editor-in-Chief.
External references below are sources recorded by the researcher agents for this Gilead Sciences forecast batch.
Primary analysis inputs
- iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
- iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
- Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
- Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
- Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.
Independent AI Advisor panel
- AI Advisors
- 14
- AI Researchers
- 11
- AI Thinkers
- 3
Sources retained from AI Researcher searches
Asset-specific · Researcher web33 available sources from this batch (125 recorded). The first 15 are shown below; expand to read the rest.
- CMS Announces Selection of Drugs for Third Cycle of Medicare Drug Price Negotiation Program, Including First-Ever Part B Drugs | CMS cms.gov
- gild-20260630 sec.gov
- GILEAD SCIENCES, INC. - Form 10-Q - FY2026 sec.gov
- GILEAD SCIENCES, INC. - Form DEF 14A - FY2026 sec.gov
- Lakefront Biotherapeutics NV - Form 6-K - FY2026 sec.gov
- Fact Sheet: President Donald J. Trump Announces Deal with Nine Additional Pharmaceutical Manufacturers to Lower Drug Prices for Americans – The White House whitehouse.gov
- Savings from Most-Favored-Nation Drug Pricing Policy – The White House whitehouse.gov
- Gilead Sciences, Inc. - Gilead Sciences Announces Second Quarter 2026 Financial Results investors.gilead.com
- Trump Strikes 9 New Pricing Agreements as Drugmakers Navigate Tariff, Regulatory Pressure | AJMC ajmc.com
- Gilead raises full-year guidance on 8% Q2 sales growth, eyes three near-term regulatory approvals allsci.com
- Gilead Wins FDA Nod for Bixlenvo, New HIV Pill | AskTraders.com % asktraders.com
- FDA approves daily HIV pill from Gilead designed to simplify treatment for some patients cnbc.com
- Drug companies sign "Most Favored Nation" deals, then raise prices anyway drugdiscoverytrends.com
- With 3 acquisitions to digest, Gilead shifts focus from M&A to pipeline that has 'never been stronger' fiercebiotech.com
- 9 pharma giants reach US drug price deals with Trump administration fiercepharma.com
Show 18 more sources
- Gilead Sciences Just Won Its Third FDA Approval in Less Than 4 Months. Is the Stock Still Underrating This Turnaround Play? | The Motley Fool fool.com
- CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results gilead.com
- Gilead Breaks Ground on New Biologics Facility as Part of 32 Billion US RD and Manufacturing Investment gilead.com
- Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito cel gilead.com
- Gilead Sciences to Acquire Arcellx to Maximize Long Term Potential of Anito cel gilead.com
- Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases gilead.com
- Gilead to Acquire Tubulis Adding Potentially Best in Class Antibody Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline gilead.com
- U.S. FDA Approves Gilead’s Bixlenvo™, a New Once Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex Regimens gilead.com
- Gilead Sciences, Inc. - Gilead Accelerates Global Access Planning for Investigational Once-Yearly Lenacapavir for HIV Prevention investors.gilead.com
- Gilead Sciences, Inc. - U.S. FDA Accepts Gilead’s Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention investors.gilead.com
- Gilead Swings To Q2 Loss On Acquisition Charges rttnews.com
- 0000882095-26-000006 s29.q4cdn.com
- 1 GILEAD SCIENCES SECOND QUARTER 2026 EARNINGS PREPARED REMARKS s29.q4cdn.com
- Gilead Sciences (GILD) Stock Forecast & Analyst Price Targets stockanalysis.com
- Gilead (GILD) 2025 earnings jump on HIV growth as 2026 guidance targets steady profits stocktitan.net
- Gilead Q2 net loss on heavy IPR&D charges | GILD Quarterly Report (10-Q) stocktitan.net
- 9 pharma companies agree to Trump's Most Favored Nation drug pricing policy thehill.com
- Gilead Sciences (GILD) stock Forecast, Price Targets and ... tickeron.com
92 additional sources are recorded in this batch; their citation details are not available in this publication.
Context retained with this Consensus
The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.
Global context snapshot
2025 Full-Year Global Market and World-Events Context
Download Archived SnapshotCoverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31
This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.
Archived context covering 2025-01-01 to 2025-12-31. Its recorded scope includes technology and capital cycle; trade and industrial policy; monetary policy. Selected highlights reflect the analysis cutoff, not current world conditions.
Show moreShow less
- File size
- 90.8K bytes
- Words
- 13.3K words
- Characters
- 90.8K characters
- Est. tokens (characters ÷ 4)
- 22.7K tokens
The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.
| Selected highlights from this archived snapshot | Date | Status |
|---|---|---|
| DeepSeek shock and AI economics reset | 2025-01-27 | OPEN ENDED TREND |
| US tariff regime escalation and trade-system rupture | 2025-02-01 | ACTIVE POLICY REGIME |
| Federal Reserve easing cycle after a prolonged hold | 2025-09-17 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
2026 Year-to-Date Global Market and World-Events Context Through September 20
Download Archived SnapshotCoverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20
January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.
Archived context covering 2026-01-01 to 2026-09-20. Its recorded scope includes monetary policy and rates; geopolitics energy and shipping; trade and industrial policy. Selected highlights reflect the analysis cutoff, not current world conditions.
Show moreShow less
- File size
- 84.8K bytes
- Words
- 12.4K words
- Characters
- 84.8K characters
- Est. tokens (characters ÷ 4)
- 21.2K tokens
Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.
| Selected highlights from this archived snapshot | Date | Status |
|---|---|---|
| Renewed monetary tightening amid persistent inflation | 2026-01-30 | ACTIVE POLICY REGIME |
| Iran/Hormuz conflict and wider energy-security disruption | 2026-02-28 | ONGOING |
| Tariff legal reset and strategic supply restrictions | 2026-02-20 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
Fundamental Context Passed as Input to the Models
Time range: Annual fiscal periods: 2014-12-31–2025-12-31, 12 periods; Quarterly fiscal periods: 2023-09-30–2026-06-30, 12 periods.
Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).
Show moreShow less
Income statement
9 fieldsdepreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields
Balance sheet
12 fieldscash · commonStockSharesOutstanding · longTermDebt · netDebt · +8 more fields
Cash flow
5 fieldscapitalExpenditures · dividendsPaid · freeCashFlow · salePurchaseOfStock · +1 more field
End of the paywalled preview
The excerpt from Deep Dive: detailed analysis to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.
Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.
Additional with full access
Individual AI Advisor reports
- Investment theses
- Bull and bear scenarios and alpha signals
- Drivers, headwinds, risks and opportunities
- Quarterly forecast rationale
- Advisor research references and configuration
Additional datasets and interactive tools
- Interactive forecast comparisons
- Available detailed financial statements
- Market history and corporate-action adjustments
- Eligible historical publication workspaces
Explore complete public research examples
These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.